Palisade Bio, Inc.

NasdaqCM:PALI Stock Report

Market Cap: US$334.8m

Palisade Bio Future Growth

Future criteria checks 0/6

Palisade Bio's earnings are forecast to decline at 4.7% per annum while its annual revenue is expected to grow at 82.7% per year. EPS is expected to grow by 15.3% per annum.

Key information

-4.7%

Earnings growth rate

15.34%

EPS growth rate

Biotechs earnings growth24.7%
Revenue growth rate82.7%
Future return on equityn/a
Analyst coverage

Good

Last updated05 May 2026

Recent future growth updates

Recent updates

Seeking Alpha • Dec 23

Palisade Bio: Gut Prodrug For IBD With Catalysts

Summary Palisade Bio’s bull thesis centers on PALI-2108. This is a gut-targeted PDE4 prodrug aiming for local efficacy with fewer systemic PDE4 side effects. The main target indications are UC and FSCD, which promise a sizable TAM if PALI-2108 ultimately succeeds. Naturally, this means PALI’s story remains early-stage and highly data-dependent. Yet, they have a compelling near-term catalyst stack. PALI’s recent October 2025 raise also materially improved their cash runway and liquidity. Using those numbers, its valuation looks compelling relative to its peers. Thus, I lean towards a speculative "Buy" rating on PALI. Read the full article on Seeking Alpha
Seeking Alpha • Oct 11

Palisade Bio announces CEO transition

Palisade Bio (NASDAQ:PALI) announced an executive leadership transition effective October 10, 2022, Thomas Hallam, Ph.D., ceased his duties as CEO. The company’s board of directors has appointed JD Finley, current CFO, as interim CEO, and Mr. Finley has assumed the duties of Dr. Hallam effective October 10, 2022. Prior to joining Palisade Bio, Mr. Finley was the CEO, president and CFO for PointAcross, a software company providing business messaging and communications services.
Seeking Alpha • Sep 15

Palisade Bio streamlines operations, including cutting 20% of employees

Palisade Bio (NASDAQ:PALI) is undergoing a program to streamline operations that includes focusing on lead clinical program LB1148 and laying off 20% of its staff. The gastrointestinal-focused biotech said it is implementing cost-savings measures of more than $1.5M per year. LB1148, a broad-spectrum serine protease inhibitor, is in phase 3 for GI surgery and phase 2 for cardiovascular surgery, both in terms of accelerating return of postoperative GI function. It is also in phase 2 in GI surgery for prevention of post-surgical abdominal adhesions. Seeking Alpha's Quant Rating views Palisade Bio (PALI) as a hold with high marks for valuation, profitability, and revisions.
Seeking Alpha • Aug 15

Palisade Bio GAAP EPS of -$0.12

Palisade Bio press release (NASDAQ:PALI): Q2 GAAP EPS of -$0.12. As of June 30, 2022, the company had cash and cash equivalents of $5M
Seeking Alpha • Jul 27

Palisade Bio begins phase 3 study testing LB1148 for postoperative return of bowel function

Palisade Bio (NASDAQ:PALI) said on Wednesday the first patient had been screened in a Phase 3 study testing its drug, LB1148, to help return bowel function in adult patients undergoing gastrointestinal surgery. The company said it was working to enroll patients and expects to complete enrollment within the next 18-24 months. The drug LB1148 is being developed for administration before the surgeries. The trial is set to enroll about 600 patients and will assess the safety and efficacy of LB1148. The primary endpoint is time to recovery of the upper and lower gastrointestinal tract following surgery. (PALI) rose 1.3% before the bell.
Seeking Alpha • Jun 29

Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy

Palisade Bio (NASDAQ:PALI) is trading 10% higher after it begun Phase 3 study evaluating its drug, LB1148, to help return bowel function in patients undergoing gastrointestinal surgery. The late-stage study will enroll about 600 patients. The primary endpoint of the study is time to recovery of the upper and lower gastrointestinal tract following surgery, which is defined as the time from the end of surgery to the toleration of food and first bowel movement.
Analysis Article • Mar 28

Palisade Bio (NASDAQ:PALI) Will Have To Spend Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Earnings and Revenue Growth Forecasts

NasdaqCM:PALI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2028N/A-66-67-615
12/31/2027N/A-46-48-336
12/31/2026N/A-34-40-206
12/31/2025N/A-17-11-11N/A
9/30/2025N/A-11-10-10N/A
6/30/2025N/A-12-10-10N/A
3/31/2025N/A-13-11-11N/A
12/31/2024N/A-14-12-12N/A
9/30/2024N/A-14-13-13N/A
6/30/2024N/A-14-12-12N/A
3/31/2024N/A-14-11-11N/A
12/31/20230-12-11-11N/A
9/30/20230-13-12-12N/A
6/30/20230-14-12-12N/A
3/31/20230-13-13-13N/A
12/31/2022N/A-15-13-13N/A
9/30/2022N/A-9-13-13N/A
6/30/2022N/A0-13-13N/A
3/31/2022N/A-27-17-17N/A
12/31/2021N/A-27-15-15N/A
9/30/2021N/A-32-13-13N/A
6/30/2021N/A-39-11-11N/A
3/31/2021N/A-12-5-5N/A
12/31/2020N/A-10-5-5N/A
9/30/2020N/A-9-5-5N/A
12/31/2019N/A-10-7-7N/A
12/31/20181-4N/A-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PALI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PALI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PALI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PALI is forecast to have no revenue next year.

High Growth Revenue: PALI is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PALI's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/07 17:29
End of Day Share Price 2026/05/07 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Palisade Bio, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William WoodB. Riley Securities, Inc.
Kumaraguru RajaBrookline Capital Markets
Mitchell KapoorH.C. Wainwright & Co.